THERAVET SA |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.696 EUR | 0.00% |
|
-10.54% | -52.00% |
| 04-23 | TheraVet SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 03-13 | TheraVet SA Announces the Launch of BIOCERA-VET Equine | CI |
| Sales 2021 | 1.94M 2.08M 166M | Sales 2022 | 1.6M 1.71M 137M | Capitalization | 8.06M 8.63M 689M |
|---|---|---|---|---|---|
| Net income 2021 | -1M -1.07M -85.54M | Net income 2022 | -2M -2.14M -171M | EV / Sales 2021 | 7.08 x |
| Net cash position 2021 | 4.63M 4.96M 396M | Net cash position 2022 | 2.14M 2.29M 183M | EV / Sales 2022 | 3.7 x |
| P/E ratio 2021 * |
-
| P/E ratio 2022 |
-3.48
x | Employees | 8 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 week | -10.54% | ||
| Current month | -28.54% | ||
| 1 month | -26.58% | ||
| 3 months | -48.82% | ||
| 6 months | -54.66% | ||
| Current year | -52.00% |
1 week
0.65
0.79
1 month
0.650.99
Current year
0.651.46
1 year
0.652.55
3 years
0.658.56
5 years
0.658.56
10 years
0.658.56
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | - | 20/11/17 | |
Rodolphe Lebrun
DFI | Director of Finance/CFO | - | 23/10/23 |
Celine Molle
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | - | 20/11/17 | |
Simon Wheeler
CHM | Chairman | - | 19/12/21 |
Nesya Goris
BRD | Director/Board Member | - | 19/12/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/05/24 | 0.696 | 0.00% | 4 082 |
| 30/04/24 | 0.696 | -0.57% | 6,416 |
| 29/04/24 | 0.7 | -1.41% | 4,836 |
| 26/04/24 | 0.71 | -8.74% | 8,021 |
| 25/04/24 | 0.778 | -1.52% | 1,043 |
Real-time Euronext Paris, May 02, 2024 at 10:20 am
More quotes
TheraVet SA is specialized in the development of pharmaceutical products for the treatment of osteoarticular diseases in pets.
At the end of 2023, the company had a portfolio of 2 products in the clinical development phase: Visco-Vet for the treatment of limping associated with osteoarthritis in dogs and Biocera-Vet for osseointegration and bone remodeling.
Calendar
06/06/2024
- Shareholders Meeting
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -52.00% | 2.4M | |
| -1.17% | 104B | |
| +2.87% | 97.47B | |
| +4.19% | 22.25B | |
| -14.77% | 21.68B | |
| -9.07% | 18.2B | |
| -39.98% | 17.02B | |
| -13.21% | 16.36B | |
| +8.55% | 14.39B | |
| +35.75% | 12.37B |
- Stock Market
- Equities
- ALVET Stock
